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PERFORMANCE OF HPV TESTS IN SCREENING 
OF YOUNG VACCINATED WOMEN- INSIGHTS 
FROM THE SHEVA STUDY
Introduction
HR-HPV based primary cervical screening is now 
being implemented in several countries. HPV 
vaccination is changing the extent and distribution of 
HPV genotypes in the population. Consequently, it is 
important for clinically validated HPV tests to be 
tested in vaccinated population to understand the 
impact of immunisation on their performance.
Scotland is well placed to achieve this as girls 
vaccinated with the bivalent vaccine as part of “catch-
up” immunisation programme have been entering the 
cervical screening programme since 2010. The 
Scottish HPV prevalence in vaccinated women 
(SHEVa) studies are designed to provide insight into 
the performance of clinically validated HPV tests in 
vaccinated women (Bhatia et al, 2016, IJC).
The present analysis focuses on the clinical 
performance of a DNA and RNA based HPV test in 
vaccinated women attending their first cervical screen.
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Follow-up (average 17.1 months) was available for 
943 women. Cases were defined as histologically
confirmed  >=CIN2 with controls as either <=CIN1 or 
two sequential negative cytology results (Table 1) 
Clinical performance of the HPV tests
Table 2 shows the performance of rtHPV and Aptima
tests in vaccinated women compared to 
unvaccinated women from SHEVA cohort. The 
sensitivity and NPV of the tests remain high but the 
specificity and PPV have reduced for both assays in 
vaccinated women. 
Samples- Cervical samples from women attending 
their first routine screen at age 20 were collected for 
national immunization surveillance and residual 
samples stored in Scottish HPV Archive. 
For this analysis, samples were collected from 993 
unvaccinated and 1007 vaccinated women between 
2010 and 2012. To enrich for disease cases in 
vaccinated women, a further 459 samples from 
vaccinated women with abnormal cytology results 
were collected between 2013 and 2014. 
HPV testing- All samples were tested using the 
rTHPV test (Abbott) and APTIMA HPV test (Hologic) 
according to manufacturers instructions.
Outcome measures- Clinical performance  of 
assays (sensitivity, specificity, positive predictive 
value (PPV) and negative predictive value (NPV) for 
the detection of CIN2+
Conclusions 
Clinically validated HPV tests maintain 
high sensitivity and NPV but the 
specificity and PPV of HPV testing as 
a primary screen is reduced in young 
vaccinated women. This has 
implications for the appropriate 
management of HPV screen-positive 
vaccinated women and underlines the 
importance of robust triage strategies. 
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Controls (<=CIN1 or 
cytology normal)
Total (N=943) 119 (35.60%) 352 (37.33%)
Unvaccinated (N= 337) 63 (18.69%) 140 (41.54%)
Vaccinated (N=606) 56 (9.47%) 212 (34.98%)
Table 1:  Overview of population
Table 2:  Clinical performance of HPV tests stratified by vaccination 
status
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